drugset
drugset / Trial / NCT01985152

A Phase Ⅰa Study of Azilsartan Trimethylethanolamine in Healthy Volunteers

NCT01985152 ↗

Phase 1 Unknown 62 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the Pharmacokinetics and safety of Azilsartan Trimethylethanolamine in healthy volunteers

Timeline

Start
2013-09
Primary completion
2013-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan Trimethylethanolamine Unknown 8.75 mg Oral
Subject Azilsartan Trimethylethanolamine Unknown 17.5 mg Oral
Subject Azilsartan Trimethylethanolamine Unknown 35 mg Oral
Subject Azilsartan Trimethylethanolamine Unknown 70 mg Oral
Subject Azilsartan Trimethylethanolamine Unknown 140 mg Oral
Subject Azilsartan Trimethylethanolamine Unknown 210 mg Oral
Subject Azilsartan Trimethylethanolamine Unknown 280 mg Oral

Indications

No indication recorded.